Loading...
01/11 03:34
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights strong initial revenues from Sephience, significant cash reserves, and positive feedback from patients and physicians, indicating growth potential. The Q&A reinforces confidence in Sephience's uptake and patient adherence, despite some lack of specific guidance. The market cap suggests a moderate reaction, but overall, the sentiment leans positive due to new product launches and strategic market expansions.
Total Revenue $211 million for the third quarter of 2025, which includes the first revenue from the Sephience launch and contributions from the DMD franchise.
Sephience Revenue $19.6 million as of September 30, 2025, with $14.4 million from the U.S. and $5.2 million ex U.S. This is the first revenue from the Sephience launch.
DMD Franchise Revenue $86 million for the quarter, with Translarna net product revenue of $51 million and Emflaza net product revenue of $35 million.
Evrysdi Royalty Revenue $71 million for the third quarter of 2025, based on Roche's global revenue of approximately $532 million.
Non-GAAP R&D Expense $91 million for the third quarter of 2025, excluding $9 million in noncash stock-based compensation expense. This is a decrease from $152 million in the third quarter of 2024, excluding $9 million in noncash stock-based compensation expense. The decrease reflects reduced spending on certain programs.
Non-GAAP SG&A Expense $74 million for the third quarter of 2025, excluding $10 million in noncash stock-based compensation expense. This is an increase from $63 million in the third quarter of 2024, excluding $10 million in noncash stock-based compensation expense, due to increased commercial activities.
Cash, Cash Equivalents, and Marketable Securities $1.68 billion as of September 30, 2025, compared to $1.14 billion as of December 31, 2024. The increase reflects the purchase of 90% of Sephience annual global net sales payment obligation for $225 million upfront and future sales-based milestone payments.
Sephience launch: Initiated global launch in Europe and the U.S., generating $19.6 million in revenue as of September 30, 2025. U.S. revenue was $14.4 million, and ex-U.S. revenue was $5.2 million. Received 521 patient start forms from U.S. centers, covering all ages, disease severities, and treatment histories. Demonstrated 70% greater reduction in phenylalanine levels compared to BH4 in a head-to-head study.
DMD franchise: Generated $86 million in revenue, with $51 million from Translarna and $35 million from Emflaza.
Evrysdi royalties: Roche's global revenue of $532 million resulted in $71 million in royalty revenue for PTC.
Geographic expansion: Sephience launched in the U.S. and Europe, with preparations for Japan launch in Q4 and recent approval in Canada. Anticipating regulatory approvals in Japan and Brazil later this year.
Financial position: Ended Q3 with $1.68 billion in cash, enabling cash flow breakeven and strategic business development activities.
Cost management: Non-GAAP R&D expense was $91 million, down from $152 million in Q3 2024. Non-GAAP SG&A expense was $74 million, up from $63 million in Q3 2024.
Sephience pricing strategy: Maintaining a narrow pricing corridor during the early launch stage.
Business development: Acquired 90% of Sephience annual global net sales payment obligation for $225 million upfront, expecting significant value creation.
Regulatory Approvals and Compliance: The company is awaiting regulatory approvals in Japan and Brazil for Sephience, which could delay market entry and revenue generation in these regions. Additionally, the need to secure pricing and reimbursement across international markets poses a challenge.
Market Access and Payer Policies: Although initial payer engagement in the U.S. has been positive, the company anticipates a stabilization of the payer mix, which could impact revenue projections. Medicaid and Medicare plans are still finalizing their policies, creating uncertainty in the payer landscape.
Supply Chain and Launch Execution: The simultaneous launch of Sephience in multiple regions, including the U.S., Europe, and upcoming markets like Japan, requires robust supply chain management and operational execution. Any disruptions could impact product availability and revenue.
Competitive Pressures: The company faces competition in the PKU treatment market, which could impact Sephience's market share and revenue growth. Additionally, maintaining brand loyalty for existing products like Translarna and Emflaza amidst generic entries is a challenge.
Economic and Financial Risks: The company has made significant financial commitments, including a $225 million upfront payment for Sephience-related obligations. While the company is well-capitalized, these financial outlays could strain resources if revenue targets are not met.
Strategic Execution Risks: The company is heavily reliant on the success of Sephience for its near-term path to profitability. Any setbacks in its adoption, efficacy perception, or market penetration could adversely affect financial performance.
Revenue Guidance: The company has narrowed its 2025 full-year revenue guidance to $750 million to $800 million, which is at the upper end of the initial revenue guidance range.
Sephience Launch and Revenue Expectations: The Sephience global launch is expected to be a foundational product for sustainable growth and near-term profitability. Sephience generated $19.6 million in revenue as of September 30, 2025, and the company anticipates continued momentum in the U.S., Europe, and upcoming launches in Japan, Canada, and Brazil.
Regulatory Approvals and Market Expansion: Regulatory approval for Sephience in Japan and Brazil is anticipated later this year, with Canada already approved. The company is preparing health technology assessment dossiers to secure pricing and reimbursement in international markets.
Huntington's Disease Program: A meeting with the FDA is planned for Q4 2025 to align on the study design for the next efficacy study and discuss the data package for a potential accelerated approval application.
Friedreich's Ataxia Program: A meeting with the FDA is planned this quarter to discuss potential next steps for the program.
Translarna NDA: The NDA for Translarna remains under FDA review.
Financial Position and Strategic Plans: The company ended Q3 2025 with $1.68 billion in cash, enabling it to reach cash flow breakeven and participate in strategic business development activities. An R&D Day is scheduled for December 2, 2025, to share progress on research programs.
The selected topic was not discussed during the call.
The earnings call highlights strong initial revenues from Sephience, significant cash reserves, and positive feedback from patients and physicians, indicating growth potential. The Q&A reinforces confidence in Sephience's uptake and patient adherence, despite some lack of specific guidance. The market cap suggests a moderate reaction, but overall, the sentiment leans positive due to new product launches and strategic market expansions.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
